Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Oct 17;12(10):2518.
doi: 10.3390/diagnostics12102518.

Radioembolization-Induced Changes in Hepatic [18F]FDG Metabolism in Non-Tumorous Liver Parenchyma

Manon N Braat  1 , Caren van Roekel  1 , Marnix G Lam  1 , Arthur J Braat  1
Affiliations

Radioembolization-Induced Changes in Hepatic [18F]FDG Metabolism in Non-Tumorous Liver Parenchyma

Manon N Braat et al. Diagnostics (Basel). .

Abstract

Background: [18F]FDG-PET/CT is increasingly used for response assessments after oncologic treatment. The known response criteria for [18F]FDG-PET/CT use healthy liver parenchyma as the reference standard. However, the [18F]FDG liver metabolism results may change as a result of the given therapy. The aim of this study was to assess changes in [18F]FDG liver metabolism after hepatic 90Y resin radioembolization. Methods: [18F]FDG-PET/CT scans prior to radioembolization and one and three months after radioembolization (consistent with the PERCIST comparability criteria), as well as 90Y-PET/CT scans, were analyzed using 3 cm VOIs. The FDG activity concentration and absorbed dose were measured. A linear mixed-effects logistic regression model and logistic mixed-effects model were used to assess the correlation between the FDG-activity concentration, absorbed dose, and biochemical changes. Results: The median SULVOI,liver at baseline was 1.8 (range = 1.2−2.8). The mean change in SULVOI,liver per month with an increase in time was 0.05 (95%CI 0.02−0.09) at p < 0.001. The median absorbed dose per VOI was 31.3 Gy (range = 0.1−82.3 Gy). The mean percent change in ΔSULVOI,liver for every Gy increase in the absorbed dose was −0.04 (95%CI −0.22−0.14) at p = 0.67. The SULblood and SULspleen results showed no increase. Conclusions: The [18F]FDG metabolism in the normal liver parenchyma is significantly but mildly increased after radioembolization, which can interfere with its use as a threshold for therapy response.

Keywords: FDG-PET; PERCIST; SIRT; radioembolization.

PubMed Disclaimer

Conflict of interest statement

The authors of this manuscript declare relationships with the following companies: BTG/Boston Scientific, Terumo, and Quirem. A. Braat is a speaker for BTG/Boston Scientific and Terumo. M. Lam receives research support from Terumo, Quirem, and Boston Scientific, and is a consultant on their behalf. The department of Radiology and Nuclear Medicine of the University Medical Center Utrecht receives royalty payments from Quirem. Their radioembolization products were, however, not used in this article. The other authors of this manuscript (C. van Roekel, M.N.G.J.A. Braat) declare no relationships with any companies whose products or services may be related to the subject matter of the article.

Figures

Figure 1
Figure 1
Flowchart of the study.
Figure 2
Figure 2
Changes in SULVOI,liver over time compared to baseline values.
Figure 3
Figure 3
Differences in SULliver (patient-level) versus biochemical toxicity. Numbers represent the different durations of biochemical toxicity determination per patient. Some patients had measurements at two follow-up times so numbers do not equal total number of patients.
Figure 4
Figure 4
Changes in SULblood (A) and SULspleen (B) over time compared to baseline and changes in splenic volume (C) over time compared to baseline.
Figure 4
Figure 4
Changes in SULblood (A) and SULspleen (B) over time compared to baseline and changes in splenic volume (C) over time compared to baseline.
Figure 5
Figure 5
Case example of visual increase in [18F]FDG activity concentration in non-tumorous liver tissue. A 75 year old woman with colorectal liver metastases underwent a [18F]FDG-PET/CTprior (A) and a [18F]FDG-PET/CTfollow-up (B) 15 days prior and 29 days after radioembolization, respectively. The images are similarly scaled (0–7 SUVlean body mass). One month after radioembolization, a reduced [18F]FDG activity concentration can be seen in the metastases, but the background non-tumorous liver activity concentration has visually increased (SULVOI,liver increase from 1.8 to 2.4 in the VOIright liver).
See this image and copyright information in PMC

References

    1. Wahl R.L., Jacene H., Kasamon Y., Lodge M.A. From RECIST to PERCIST: Evolving Considerations for PET response criteria in solid tumors. J. Nucl. Med. 2009;50((Suppl. 1)):122s–150s. doi: 10.2967/jnumed.108.057307. - DOI - PMC - PubMed
    1. Young H., Baum R., Cremerius U., Herholz K., Hoekstra O., Lammertsma A.A., Pruim J., Price P. Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography: Review and 1999 EORTC recommendations. European Organization for Research and Treatment of Cancer (EORTC) PET Study Group. Eur. J. Cancer. 1999;35:1773–1782. doi: 10.1016/S0959-8049(99)00229-4. - DOI - PubMed
    1. Skougaard K., Nielsen D., Jensen B.V., Hendel H.W. Comparison of EORTC criteria and PERCIST for PET/CT response evaluation of patients with metastatic colorectal cancer treated with irinotecan and cetuximab. J. Nucl. Med. 2013;54:1026–1031. doi: 10.2967/jnumed.112.111757. - DOI - PubMed
    1. Paquet N., Albert A., Foidart J., Hustinx R. Within-patient variability of (18)F-FDG: Standardized uptake values in normal tissues. J. Nucl. Med. 2004;45:784–788. - PubMed
    1. Kanstrup I.L., Klausen T.L., Bojsen-Moller J., Magnusson P., Zerahn B. Variability and reproducibility of hepatic FDG uptake measured as SUV as well as tissue-to-blood background ratio using positron emission tomography in healthy humans. Clin. Physiol. Funct. Imaging. 2009;29:108–113. doi: 10.1111/j.1475-097X.2008.00846.x. - DOI - PubMed

LinkOut - more resources